Evidence map›Paper›PMID 37140493›Full record

ArticleAnnals of emergency medicine2023

Implementing Programs to Initiate Buprenorphine for Opioid Use Disorder Treatment in High-Need, Low-Resource Emergency Departments: A Nonrandomized Controlled Trial.

Ryan P McCormack, John Rotrosen, Phoebe Gauthier, Gail D'Onofrio, David A Fiellin, Lisa A Marsch, Patricia Novo, David Liu, E Jennifer Edelman, Sarah Farkas and 8 more

Abstract readControlled Clinical TrialMulticenter Study
In one paragraph

Article in Annals of emergency medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Trial
  2. Article
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Ryan P McCormackNew York University Grossman School of Medicine, New York, NY. Electronic address: Ryan.McCormack@nyulangone.org.
John RotrosenNew York University Grossman School of Medicine, New York, NY.
Phoebe GauthierGeisel School of Medicine at Dartmouth College, Hanover, NH.
Gail D'OnofrioYale School of Medicine, Department of Emergency Medicine, New Haven, CT; Yale Program in Addiction Medicine, Yale School of Medicine, New Haven, CT; Yale School of Medicine, Department of Medicine, New Haven, CT; Yale School of Public Health, New Haven, CT.
David A FiellinYale School of Medicine, Department of Emergency Medicine, New Haven, CT; Yale Program in Addiction Medicine, Yale School of Medicine, New Haven, CT; Yale School of Medicine, Department of Medicine, New Haven, CT; Yale School of Public Health, New Haven, CT.
Lisa A MarschGeisel School of Medicine at Dartmouth College, Hanover, NH.
Patricia NovoNew York University Grossman School of Medicine, New York, NY.
David LiuNational Institute on Drug Abuse, Rockville, MD.
E Jennifer EdelmanYale Program in Addiction Medicine, Yale School of Medicine, New Haven, CT; Yale School of Medicine, Department of Medicine, New Haven, CT; Yale School of Public Health, New Haven, CT.
Sarah FarkasNew York University Grossman School of Medicine, New York, NY.
Abigail G MatthewsEMMES Company, LLC, Rockville, MD.
Caroline MulatyaEMMES Company, LLC, Rockville, MD.
Dagmar SalazarEMMES Company, LLC, Rockville, MD.
Jeremy WolffEMMES Company, LLC, Rockville, MD.
Randolph KnightSpringfield Hospital, Springfield, VT.
William GoodmanSteward Health Care, Methuen, MA.
Joseph WilliamsYale School of Public Health, New Haven, CT.
Kathryn HawkYale School of Medicine, Department of Emergency Medicine, New Haven, CT; Yale Program in Addiction Medicine, Yale School of Medicine, New Haven, CT; Yale School of Public Health, New Haven, CT.

Funding

Project-003UG1DA013035 · NIDA · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI Aimee N Campbell, Jennifer McNeely · 2015 to 2026
$130.3M
Yale Clinical and Translational Science Award (U Component)UL1TR001863 · NCATS · YALE UNIVERSITY · PI John H. Krystal, LUCILA OHNO-MACHADO · 2016 to 2026
$102.9M
Project-002UG1DA040309 · NIDA · DARTMOUTH COLLEGE · PI Lisa A. Marsch · 2015 to 2026
$37.9M
Treatment Development & Evaluation CoreP30DA029926 · NIDA · DARTMOUTH COLLEGE · PI Lisa A. Marsch · 2011 to 2026
$21.5M
NCATS NIH HHS UL1 TR001863NIDA NIH HHS P30 DA029926NIDA NIH HHS UG1 DA013035NIDA NIH HHS UG1 DA040309
6 · The paper itself

Abstract

STUDY

objectiveWe hypothesized that implementation facilitation would enable us to rapidly and effectively implement emergency department (ED)-initiated buprenorphine programs in rural and urban settings with high-need, limited resources and dissimilar staffing structures.

methodsThis multicenter implementation study employed implementation facilitation using a participatory action research approach to develop, introduce, and refine site-specific clinical protocols for ED-initiated buprenorphine and referral in 3 EDs not previously initiating buprenorphine. We assessed feasibility, acceptability, and effectiveness by triangulating mixed-methods formative evaluation data (focus groups/interviews and pre/post surveys involving staff, patients, and stakeholders), patients' medical records, and 30-day outcomes from a purposive sample of 40 buprenorphine-receiving patient-participants who met research eligibility criteria (English-speaking, medically stable, locator information, nonprisoners). We estimated the primary implementation outcome (proportion receiving ED-initiated buprenorphine among candidates) and the main secondary outcome (30-day treatment engagement) using Bayesian methods.

resultsWithin 3 months of initiating the implementation facilitation activities, each site implemented buprenorphine programs. During the 6-month programmatic evaluation, there were 134 ED-buprenorphine candidates among 2,522 encounters involving opioid use. A total of 52 (41.6%) practitioners initiated buprenorphine administration to 112 (85.1%; 95% confidence interval [CI] 79.7% to 90.4%) unique patients. Among 40 enrolled patient-participants, 49.0% (35.6% to 62.5%) were engaged in addiction treatment 30 days later (confirmed); 26 (68.4%) reported attending one or more treatment visits; there was a 4-fold decrease in self-reported overdose events (odds ratio [OR] 4.03; 95% CI 1.27 to 12.75). The ED clinician readiness increased by a median of 5.02 (95% CI: 3.56 to 6.47) from 1.92/10 to 6.95/10 (n(pre)=80, n(post)=83).

conclusionsThe implementation facilitation enabled us to effectively implement ED-based buprenorphine programs across heterogeneous ED settings rapidly, which was associated with promising implementation and exploratory patient-level outcomes.

Indexed as

BuprenorphineNarcotic AntagonistsOpioid-Related DisordersAdultClinical ProtocolsEmergency Service, HospitalFemaleHumansMaleBuprenorphineNarcotic Antagonists

Identifiers

PMID37140493
PMCPMC10524047

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.